Last reviewed · How we verify
Intravenous Carbamazepine
At a glance
| Generic name | Intravenous Carbamazepine |
|---|---|
| Also known as | IV CBZ |
| Sponsor | Lundbeck LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults (PHASE1)
- Efficacy of SMOF Lipid in the Management of Acute Poisoning With Carbamazepine (PHASE2)
- Safety of Autologous MSC Infusion to Treat Epilepsy (PHASE1, PHASE2)
- Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma (PHASE1, PHASE2)
- Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy (PHASE3)
- A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Carbamazepine CI brief — competitive landscape report
- Intravenous Carbamazepine updates RSS · CI watch RSS
- Lundbeck LLC portfolio CI